Dr. Paul A. Hamlin, MD

Dr. Hamlin practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Hamlin's NPI, 1376514315, was assigned on January 29, 2006. Dr. Hamlin graduated from SUNY Downstate Health Sciences University in 1997. Dr. Hamlin holds New York license 211763.

Dr. Hamlin's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Hamlin's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group. Dmand AI also links Dr. Hamlin to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hamlin practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Hamlin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Hamlin is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Hamlin's licenses on file in 4 states: New York, Florida, Connecticut and New Jersey.

Dmand AI lists breast cancer, chronic leukemia, colorectal cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Hamlin treats.

CMS data shows 726 Medicare services from Dr. Hamlin across 5 procedure codes in 2024, for 281 Medicare patients. Medicare paid $66,037 for them. Every service was in an office.

CMS counts 281 Medicare patients who saw Dr. Hamlin in 2024. The largest group is 75 to 84, with 119 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hamlin's median patient age at 74, with 48% women.

In 2024, Dr. Hamlin wrote 191 Medicare Part D claims for 46 patients. 70% of them were for generic drugs. CMS names the drug for 115 of them, across 6 drugs with 11 or more claims each, at $475,592 in total drug cost. In 2023, CMS named 127 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Hamlin for performance year 2024, reported as part of a group. Dr. Hamlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hamlin as offering telehealth.

Dmand AI links 121 papers to Dr. Hamlin, published from 2003 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Mantle-Cell. Dr. Hamlin has published most often in Br J Haematol. Dr. Hamlin's most frequent co-authors are Andrew D. Zelenetz, MD, Craig H. Moskowitz, MD and Ariela Noy, MD.

Dmand AI links Dr. Hamlin to 5 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Lymphoma, Lymphoma, Large B-Cell, Diffuse and Lymphoma, B-Cell. Memorial Sloan Kettering Cancer Center sponsors the most, 4.

CMS Open Payments shows 38 general payments to Dr. Hamlin from 13 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 67% of the total. Janssen Pharmaceuticals, Inc paid the most, $8,805.

Dr. Hamlin graduated from SUNY Downstate Health Sciences University in 1997. Dr. Hamlin is a member of ASCO.

Dr. Hamlin is in network with 13 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.